|
C11ORF61 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.04410000434774E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.29639999968801E-07 |
| Normal-vs-Stage2 |
2.151300E-04 |
| Normal-vs-Stage3 |
1.03870000045525E-07 |
| Normal-vs-Stage4 |
6.25690000000123E-05 |
| Stage1-vs-Stage2 |
8.760400E-01 |
| Stage1-vs-Stage3 |
1.733780E-01 |
| Stage1-vs-Stage4 |
5.741400E-01 |
| Stage2-vs-Stage3 |
4.547200E-01 |
| Stage2-vs-Stage4 |
7.724000E-01 |
| Stage3-vs-Stage4 |
6.883200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.83539999549276E-08 |
| Normal-vs-AfricanAmerican |
7.369600E-04 |
| Normal-vs-Asian |
1.633940E-02 |
| Caucasian-vs-AfricanAmerican |
9.538400E-01 |
| Caucasian-vs-Asian |
5.506300E-02 |
| AfricanAmerican-vs-Asian |
2.359600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.449200E-04 |
| Normal-vs-Female |
2.98809998966476E-09 |
| Male-vs-Female |
1.068360E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.88940000001826E-07 |
| Normal-vs-Age(41-60Yrs) |
8.29400000013081E-07 |
| Normal-vs-Age(61-80Yrs) |
6.773399999771E-07 |
| Normal-vs-Age(81-100Yrs) |
2.84740000000561E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.088800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.250200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.145900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.704400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.749800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.387800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.80325999999953E-05 |
| Classical-VS-Follicular |
9.602200E-01 |
| Classical-VS-Other |
4.363600E-01 |
| Classical-VS-Normal |
5.97320000017554E-07 |
| Tall-VS-Follicular |
4.623300E-04 |
| Tall-VS-Other |
1.028760E-01 |
| Tall-VS-Normal |
3.09740011417148E-11 |
| Follicular-VS-Other |
3.077000E-01 |
| Follicular-VS-Normal |
2.378500E-04 |
| Other-VS-Normal |
6.484200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.44599999973849E-07 |
| Normal-vs-N1 |
1.818030E-02 |
| N0-vs-N1 |
1.664010E-01 |
|
|
